Delivery Order SPE2DB20D3101-SPE2DB25FRUX2
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,101.85 to AmerisourceBergen Drug Corp for the supply of Emgality 120 mg/ml pen/ml, a pharmaceutical product used in migraine treatment. This firm fixed price delivery order, issued on September 10, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $2,074.80 to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen/ml, a pharmaceutical product used in migraine treatment. This non-competitive, firm fixed-price delivery order was issued on July 31, 2025, with an ultimate completion date of August 1, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $2,119.39 to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen/ml, a pharmaceutical product for medical supply needs. This firm fixed-price delivery order, awarded on September 8, 2025, with an ultimate completion date of September 9, 2025, represents a child contract under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA. The award was made through open competition with no set-aside designation,...
- The Defense Logistics Agency awarded a delivery order valued at $1,213.80 to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injectors, with an ultimate completion date of July 29, 2025. The contract, issued on July 28, 2025, employs firm fixed-price pricing and was awarded through open competition with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a...
- The Defense Logistics Agency awarded a delivery order valued at $3,309.37 to AmerisourceBergen Drug Corp for the supply of Emgality 120 mg/ml pen injectors. This firm fixed price, competitively awarded contract was issued on August 5, 2025, with an ultimate completion date of August 6, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $1,037.40 to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pens on July 30, 2025, with completion scheduled for July 31, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation. The contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania, where AmerisourceBergen operates as a major pharmaceutical distributor and critical vendor for...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on September 10, 2025, for the supply of Emgality 120 mg/ml pens, a migraine treatment medication. This competitively awarded, non-set-aside contract has a ceiling value of $1,037.40 with a firm fixed price structure and an ultimate completion date of September 11, 2025. The product will be delivered to the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $3,034.80 to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors. This firm fixed-price, competitively awarded contract was executed on August 4, 2025, with an ultimate completion date of August 5, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. No set-aside designation was applied to this award. This...
- The Defense Logistics Agency awarded a $1,729.00 firm fixed price delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors, with an ultimate completion date of July 25, 2025. This non-set-aside competitive award represents a single delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to the contractor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $1,990.63 to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors, with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, serves as the...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRUX2Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,729.00 to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen/mL, a pharmaceutical product used in migraine treatment. The contract was awarded on September 9, 2025, with an ultimate completion date of September 10, 2025, using firm fixed pricing with no set-aside designation. Performance will occur at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a total value of $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the DLA's Medical Supply Chain. The company's extensive federal contract portfolio demonstrates capability in delivering a comprehensive range of pharmaceutical products, including specialty medications, brand-name and generic drugs, and medical supplies across multiple therapeutic domains. The SPE2DX umbrella contract enables AmerisourceBergen to fulfill pharmaceutical supply requirements for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems, with the DLA currently planning next-generation Pharmaceutical Prime Vendor Global Program Generation V contracts intended for multiple regional awards.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 9/9/25 |